Recent evidence is proving that COVID19 causes serious white matter damage much like that caused by stroke. I am sharing this with everyone as it is quite clear that my not having sustained neurological injury from my experience with CV19 last April is due to my intensive use of transcranial photobiomodulation therapy. I treated myself with the Cognitolite device 2-4xdaiky for 5 weeks during the period I was infected and then 3-5 x / week thereafter. I also used 5 doses of clarithromycin, 2G vitC 3-4x/day, 5000iu D3, 50mcg zinc.
There is published evidence that this type of stimulation has improved healing rates against viruses eg, MRSA and improved cognitive cognitive functions of people struggling with various forms of dementia.
I encourage the use of near infrared LED light stimulation and am participating in several studies to further describe the mechanism of action.
see the equipment section of this website for several options including the Cognitolite now available for purchase.
This report underscores the importance of increasing efforts to recruit communities of color to participate in ongoing clinical trials of innovative dementia treatments. Quietmind Fdn. has succeeded in recruiting 12% of the forty subjects in it's most recent trial on the efficacy of twice-daily, self-administered, transcranial and intraocular near-infrared (1068nm) photobiomodulation therapy. We have to find ways to encourage greater participation from these communities in order to determine the disparities in response and therefor how best to modify treatment protocols to produce better clinical outcomes.
QMF will soon be initiating several home-based, self-administered, clinical trial protocols using different noninvasive, non-drug therapeutic applications of infrared-light and pulsed electromagnetic stimulation. Please contact us through the website or by phone (610) 940-0488 to inquire and enroll as there will be a limited number of subjects accepted.
January 5, 2021Disparities Persist in Dementia Risk of Black and White AdultsMary Stroka
More work is needed to identify and address modifiable sources of persistent racial disparities in US dementia prevalence.The ratio of dementia risk across non-Hispanic Black and White individuals in the United States does not appear to have changed between 2000 and 2016, researchers found in a study published in JAMA Neurology.
Several studies have reported that the risk of dementia is higher in non-Hispanic Black individuals than in non-Hispanic White individuals. Using data from the US Health and Retirement Study (HRS), a nationally representative study of adults aged 50 and older, the researchers sought to examine whether relative racial disparities in dementia in the US, both in terms of relative prevalence and relative incidence of dementia, changed from 2000 to 2016.
The researchers analyzed data from 9 HRS waves spanning 2000 through 2016. Each wave (which had a range of 6322 to 7579 eligible participants per wave) became a cross-sectional study to quantify racial disparities in the prevalence of dementia at 2-year intervals from 2000 through 2016. The researchers estimated trends in racial disparities over that time using the data from all 9 waves.
Subcohorts (which ranged in size from 5322 to 5961 participants) with 4 years of follow-up were nested within the larger longitudinal HRS to quantify racial disparities over calendar periods, with baseline years in 2000 to 2012. All subcohorts’ data was then combined.
Today’s Top Picks for You on Psychiatry Advisor
Teen Suicide Rate Quadrupled Over the Past DecadeDementia May Contribute to More Deaths Than Previously ThoughtPoor Dental Health May Increase Risk for Incident Dementia, MCI
Participants who had an algorithmic dementia diagnosis in the baseline year were excluded from subcohorts, and subcohort participants who did not have a diagnosis at the end of 2 waves of follow-up were censored.
The researchers conducted all analyses using the Expert Model, LASSO (least absolute shrinkage and selection operator), and Modified Hurd Algorithms, which predict dementia status based on sociodemographic characteristics, physical health, and cognitive health collected at HRS interview. All 3 algorithms were designed for use in HRS-based studies of racial and ethnic disparities in dementia by having similar out-of-sample sensitivity and specificity across non-Hispanic White and non-Hispanic Black subgroups.
The study authors applied HRS sampling weights to adjust for differential probability of inclusion and accounted for geographic stratification and clustering when estimating standard errors. Data from non-Hispanic Black and non-Hispanic White HRS participants who were aged 70 and older at each wave to whom they could assign an algorithmic dementia diagnosis were analyzed. Weighted regression models were used to estimate crude dementia prevalence ratios and to estimate and quantify time trends in dementia incidence. Race-specific distribution of age and sex in the year 2000 were standardized.
The Expert Model and LASSO algorithms classified an average of 20% of participants as having dementia while the Modified Hurd algorithm classified 18% of participants as having dementia. All 3 algorithms found that non-Hispanic Black participants had about a 1.5 to 1.9 times higher prevalence of dementia compared with non-Hispanic White participants in all waves in both crude and standardized estimates.
Overall, dementia prevalence declined with time in both crude and standardized estimates, and point estimates suggested a slight decline in the crude prevalence ratio comparing the groups in later years, but relative dementia prevalence across both groups did not change substantially over time. After age and sex standardization, there was no evidence of a shrinking racial disparity over time.
Across all subcohorts, non-Hispanic Black participants had an approximately 1.4 to 1.8 times higher incidence of dementia in comparison with non-Hispanic White participants. Analyses using the Expert Model or Modified Hurd algorithms to ascertain dementia status suggested no change over time, whereas analyses using the LASSO model suggested declining dementia incidence with time only in age- and sex-standardized analyses.
Limitations of the study included the use of an algorithm to ascertain dementia and the focus on the prevalence and incidence of the clinical syndrome of dementia rather than biomarker-based diagnoses of Alzheimer disease.
“Although our findings suggest stable or declining dementia risk overall, we found no evidence to suggest that relative racial disparities in dementia risk have narrowed between 2000 and 2016,” the authors said.
Power MC, Bennett EE, Turner RW, et al. Trends in relative incidence and prevalence of dementia across non-Hispanic Black and White individuals in the United States, 2000-2016. JAMA Neurol. Published online November 30, 2020. doi:10.1001/jamaneurol.2020.4471
The gross politicizing of the COVID 19 pandemic has crippled the relevant process of scientific dialogue and exploration leaving us without a shred of alignment as to how best to treat this disease and pinning far too much hope on the vaccination process. There are important insights regarding the use of existing treatments like ivermectin and hydrochloroquine and infrared photobiomodulation that are not being taken seriously enough here in the USA while other countries are saving lives and decreasing the disasterous effects of lockdowns on the economy. Quietmind is working with Durham University and other research groups to better understand the use of PBM for treating CV19 symptoms and helping to prevent infection by boosting immune responsiveness. Take this article seriously and prepare your own lines of defense against this terrible disease.
I used 2G oral Vit C every 2 hours for several weeks to help reduce COVID 19 pneumonia symptoms along with zinc and D3 and 1070nm 4x daily transcranial infrared light stimulation.
This paper shows IV Vit.C helped reduce CV19 pneumonia symptoms in Chinese patients. We need to be taking these steps to help ourselves boost our immune system and reduce symptom severity and post infection neurological damage.
We have a transcranial photobiomodulation device available now that is easy to use and versatile for improving cognitive functioning and helping reduce stress related anxiety and depression. See our website for details.
This is a new paper that we think helps to clarify how photobiomodulation should be viewed as an adjunctive or combination therapy. Its use as a way to activate biochemical and nanoparticle-based therapeutics is a direct pairing of noninvasive and more invasive therapeutic strategies. We have studied, validated and are now combining PBM with neurofeedback and TDCS/TACS for dementing illnesses as well as movement disorders and traumatic brain injuries. This is definitely the beginning of what will be growing trend as Pharma expands its position in both digital neurotherapeutics and electroceuticals.
There's been a fair amount of discussion recently about frequency enhanced water and how it may assist in healing and immune system protection etc. I found this video to be a good introduction to the basic concepts involved in the transformation of water when it is exposed to electromagnetic energy. The absorption of EM energy across a wide frequency band suggests that water may transmit or resonate with frequencies in our body in useful ways. See what you think and do share your thoughts here in the comment section.
This paper helps to underscore the value of Quantitative EEG (QEEG) assessment in the differentiation of memory loss conditions, specifically Alzheimer's, Frontotemporal and Vascular dementia which are the most prevalent forms in our population. It is critically important to be able to corretly identify the nature of someone's symptoms so that specific measures can be employed to rhelp them recover. Our work with neurofeedback and photobiomodulation has been able to markedly improve patients' cogntiive and behavioral functioning specifically becuase we used the QEEG customize treatment to their particular neurophysiological and functional deficits. It also helps to clarify that the QEEG and neurofeedback training are therapeutic in terms of improving neural connectivity but are not tissue-level interventions like photobiomodulation. The combined use of these tools is what we see as the most effective intervention strategy currently available especially when combined with functional and integrative biomedical protocols, e.g., RECODE and Bredesen treatment programs.
This brief segment on Canadian televisin shows the Vielight Neuro device and discusses some of the research being done now to show it has an impact on dementia and possibly PTSD symptoms. We know this to be the case and are glad to see it making it onto the mainstream media outlets.
Please share this with your friends and colleagues and let them know that Quietmind is providing discounted pricing up to 20% to people who are participating in our studies. We also offer free clinical and technical support which can make the difference between geting the results you want from this investment in improving your health.
I've often been asked about the use of medication in treating emotional and behavioral disorders and my standard response is that one should use medication to make it possibl to work in psychotherapy. The idea that drugs are going to resolve emotional challenges without any need to explore these problems consciously and modify ones thinking and other behavior is hard to fathom at best. I've become involved with the use of nondrug noninvasive methods of treatment for the simple reason that they work and have little to no side effects and are cost effective by orders of magnitude especically when considering them being used by the general population. This doesn't mean that I don't include psychotherapeutic work both cognitive and affective in the course of my working with people. I think it is important to educate teh public as to the corporate drug industry marketing mythology regarding the idea that psychiatric disorders are brain illnesses and can be 'cured' or 'treated' with specialized medications. The Harvard Psychiatry review paper linked here outlines the realities of this myth making effort over the last 30+ years. I'm pleased to see this finally being articulated in an esteemed journal and hope that it has broad impact on the clinicians and those seeking relief from emotional pain that can manifest as physical symptoms. I also hope we can begin to discriminate symptoms born of real biophysical disorders, e.g., traumatic brain injury, heavy metal or mold toxicity, Lyme disease and/or other tick-born illnesses that can cause neuropsychiatric symptoms of almost any that are outlined in the DSMV. We need to get smarter about all this especially now with all the consequences that will result from millions of people having had COVID 19 infection. It is delusional to think there won't be longer term consequences for our society especially as the evidence becomes available regarding the downstream neurological consequences from COVID 19.
For those of us who have been engaged in the field of EEG biofeedback and neurotherapies in general, this announcement has a double edged impact. I am both thrilled and irritated at such an announcement as it offers us some important ways to think and develop strategies for enhancing treatment models and irritated that there wasn't a single reference to QEEG or neurofeedback in the paper or references. Obviously, much more work is needed to engage the neuroscience and biomedical engineering community and the evidence is there to construct more sensitive measurement and feedback systems that can then provide us with machine learning technology that will facilitate continuous iprocess mprovement. QMF is investing in BMI systems that can discriminate and quantize human intention to control digital outputs so the algorithms being established here can be leveraged in developing future generations of neural prosthetics.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.